Stock Research for CYTX


Featured Broker: Ally Invest

Get the due diligence for another stock.


CYTX Stock Chart & Research Data

The CYTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CYTX Due diligence Resources & Stock Charts

The CYTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTX Detailed Price Forecast - CNN Money CNN View CYTX Detailed Summary - Google Finance
Yahoo View CYTX Detailed Summary - Yahoo! Finance Zacks View CYTX Stock Research & Analysis -

Stock Analysis

TradeIdeas View CYTX Trends & Analysis - Trade-Ideas Barrons View CYTX Major Holders - Barrons
NASDAQ View CYTX Call Transcripts - NASDAQ Seeking View CYTX Breaking News & Analysis - Seeking Alpha
Spotlight View CYTX Annual Report - OTC Report View CYTX OTC Short Report -
TradeKing View CYTX Fundamentals - TradeKing Charts View CYTX SEC Filings - Bar Chart
WSJ View Historical Prices for CYTX - The WSJ Morningstar View Performance/Total Return for CYTX - Morningstar
MarketWatch View the Analyst Estimates for CYTX - MarketWatch CNBC View the Earnings History for CYTX - CNBC
StockMarketWatch View the CYTX Earnings - StockMarketWatch MacroAxis View CYTX Buy or Sell Recommendations - MacroAxis
Bullish View the CYTX Bullish Patterns - American Bulls Short Pains View CYTX Short Pain Metrics -

Social Media Mentions

StockTwits View CYTX Stock Mentions - StockTwits PennyStocks View CYTX Stock Mentions - PennyStockTweets
Twitter View CYTX Stock Mentions - Twitter Invest Hub View CYTX Investment Forum News - Investor Hub
Yahoo View CYTX Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTX - Insider Cow View Insider Transactions for CYTX - Insider Cow
CNBC View CYTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTX - OTC Markets
Yahoo View Insider Transactions for CYTX - Yahoo! Finance NASDAQ View Institutional Holdings for CYTX - NASDAQ

Stock Charts

FinViz View CYTX Stock Insight & Charts - StockCharts View CYTX Investment Charts -
BarChart View CYTX Stock Overview & Charts - BarChart Trading View View CYTX User Generated Charts - Trading View

Latest Financial News for CYTX

Cytori Therapeutics Inc (NASDAQ:CYTX) Is Expected To Breakeven
Posted on Wednesday September 26, 2018

Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical

Cytori's Chemotherapy Candidate Gets Orphan Drug Status
Posted on Tuesday September 18, 2018

Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation
Posted on Monday September 17, 2018

The FDA’s Orphan Drug Designation Program provides orphan status to drugs, such as ATI-1123, which are intended for the safe and effective treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S.  Sponsors of a drug receiving orphan designation qualify for various incentives including tax credits for clinical testing, 7 years of marketing exclusivity following FDA approval, and a waiver of prescription drug user fees. Small cell lung cancer (SCLC), which accounts for approximately 15% of bronchogenic carcinomas with 33,375 new cases and 23,380 deaths estimated for 2017, has been identified by Cytori as a compelling target for ATI-1123.  While SCLC is responsive to chemotherapy and radiation therapy, cure occurs only in ~20% of patients, generally restricted to those with limited stage disease.  The remaining 80% of patients, including all patients with extensive disease, relapse within months of completing their initial therapy.

Edited Transcript of CYTX earnings conference call or presentation 14-Aug-18 9:30pm GMT
Posted on Friday August 31, 2018

Q2 2018 Cytori Therapeutics Inc Earnings Call

Stock Market & Investing Books

Enter a stock symbol to view the stock details.